Glenmark Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Broad-based growth, India leads: Glenmark continues to significantly outperform the Indian pharmaceutical market, driven by chronic respiratory and oncology, while most global markets delivered strong growth.
• Innovation pipeline now has a 10-year roadmap: Management laid out a two-phase journey: the next 5 years driven by 7–8 partnered innovative assets already launching, followed by a second wave of wholly-owned immunology assets.
• U.S. recovery hinges on near-term FDA action: The Monroe facility received a VAI classification, and the company is "hoping" for a quick Flovent 44 approval; these are the gatekeepers for a meaningful U.S. uptick in FY27.
• Margin uplift is an FY28 story: Current EBITDA margins around 23% are expected to stay range-bound until Aumolertinib and Hengrui assets commercialize broadly, at which point operating leverage on a built-out cost base should kick in.
• What to watch next quarter: Whether Flovent 44 and other respiratory products secure Q4 approvals, the pace of Monroe’s commercial production ramp, and any concrete progress on the MDL settlement’s remaining classes.

Innovation Pipeline: The 10-Year Arc

• Two distinct waves: The next 5 years belong to 7–8 partnered assets already in or nearing the market (Hansoh, Hengrui, envafolimab, Ryaltris, WINLEVI, TEVIMBRA, BRUKINSA); the following 5 years will be driven by wholly-owned assets like ISB 2001 and the immunology portfolio.
• Oncology build-out: TEVIMBRA and BRUKINSA, launched in India in Q1, have seen very strong uptake as differentiated treatments for solid and hematological tumors and are expected to meaningfully contribute over the next 2–3 years.
• Aumolertinib (third-generation EGFR TKI, partnered with Hansoh): Marketing authorization applications planned for H1 CY2026, with commercial launch anticipated in H2 FY27 across Middle East, Africa, Southeast Asia, Australia, New Zealand, Russia/CIS and selected Caribbean countries.
• Trastuzumab Rezetecan (partnered with Hengrui): First wave of marketing authorization applications expected to begin Q1 FY27.
• ISB 2301 (first-in-class multi-specific NK-cell engager for solid tumors): Clinical candidate selected October 2025, entered IND-enabling stage; IND filing expected before end of calendar year 2026.
• ISB 880 (partnered with Almirall): Phase II initiated; Almirall plans proof-of-concept studies for additional inflammatory skin diseases.
• ISB 830: Phase I initiated Q1 CY2025, initial data presented at EADV September 2025; company is actively evaluating the most promising path forward to accelerate development.
• Partnering visibility withheld: Management declined to give any visibility on further partnering scope for current or new assets in the next 6–9 months, citing optimal timing as the challenge.

Glenn Saldanha: "The next 5 years, right, will highly -- will be contributed by these 7, 8 innovative assets, right? The Hansoh, Hengrui, envafolimab, Ryaltris, WINLEVI, TEVIMBRA, BRUKINSA, I mean these are the next 5 years. And then post that, the following 5 years, will be all about 2001 and some of these immunology assets and some of the rest of our portfolio. So I think that's the next 10-year journey right for the company, right, on the innovation side."

U.S. Business: The Monroe-Flovent Inflection

• Monroe facility cleared: Received EIR from US FDA in November 2025 with Voluntary Action Indicated status; commercial production begins this quarter with 1–2 approved products, about 3 products next year with filings.
• Monroe economics: At the operating level, breakeven is about 4 years from today; the site will file at least 3 products every year, focused exclusively on very complex injectables, not run-of-the-mill products.
• Flovent 44: Multiple discussions with the FDA are underway; management is "hoping we'll get an approval very quickly" but gave no specific timeline.
• Q4 respiratory catalyst: Beyond Flovent, a nasal spray and various other respiratory products could secure approval in Q4, which would drive the strong FY26 finish management expects.
• FY27 U.S. drivers: Flovent 44 (and possibly another strength) plus at least 2 of 3 sole first-to-file opportunities in H2 FY27; FY28 and beyond will be driven by Monroe injectable approvals and additional complex respiratory filings expected in the next 3–6 months.
• Manufacturing footprint: Bulk of U.S. filings now come from Aurangabad and Monroe plants; Goa and Indore remain under warning letter, with products tech-transferred to U.S. CMOs; Baddi has completely discontinued U.S. commercialization and filings.

Glenn Saldanha: "We've had multiple discussions with the agency, and we are very close to -- we're hoping we'll get an approval very quickly on Flovent 44."

Regional Performance

RYALTRIS & Branded Portfolio

• RYALTRIS will cross \$100M this year: Sales are broad-based with no single geography contributing more than 20–25%; Europe is a big driver alongside Russia, Australia and multiple other countries.
• RYALTRIS expansion: China approval secured October 2025, launch expected Q1 FY27; Thailand launch planned Q4 this year via partner Organon; 10–12 additional market launches expected over the next few quarters; Brazilian approval expected.
• RYALTRIS ambition: Management sees getting to \$200–250 million over the next 3–5 years as "not a huge challenge."
• WINLEVI: EU marketing authorization received October 2025 via partner Cosmo; Glenmark planning commercial launch in licensed European territories by Q1 FY27.
• Lirafit (first-to-launch biosimilar of liraglutide): Holds clear market leadership in the liraglutide market and provides a segue for other GLP-1 agonists.
• JABRYUS (partnered with Pfizer, launched January 2024): Well received by dermatologists for moderate-to-severe atopic dermatitis.
• Nebzmart GFB Smartules and Glenmark Airz FB Smartules: World's first nebulized fixed-dose triple therapy for COPD launched; clinical study in India demonstrated rapid improvement in lung function and better control of breathlessness.

Margins & Financials

• Gross margin pressure: Impacted by product mix and geographical mix; management expects recovery as new product approvals in Q4 drive an uptick.
• Operating leverage offset: Good operating leverage helped overall margin despite the gross margin headwind.
• Other expenses: Q3 appeared lower due to phasing and booking issues; inflationary impact is expected overall.
• Margin uplift deferred to FY28: The real uplift from the current ~23% EBITDA level will happen from FY28 onwards, when Aumolertinib is fully commercialized in many markets and Hengrui assets begin commercializing in some markets; operating leverage will kick in on a cost base already built out.
• Debt: Net cash positive; on track to beat the target of zero debt by March 2026.
• Working capital: Targeting 115 net working capital days by March 2026, with plans to continue improving further.
• Capex: Approximately INR 800 crores for next year, covering ongoing capex, plant expansion and in-licensing products.
• Milestone payments: No big amounts anticipated on any of the 3 innovative assets; payments are more back-ended, royalty-based and sales-linked.
• Currency impact: Depreciation sits across multiple parts of the P&L and is difficult to quantify precisely; the exceptional item currency difference was only ₹7.3 crore.

Glenn Saldanha: "I would anticipate a lot of this will start playing up from FY '28, not '27. By '28, you'll have Aumolertinib fully commercialized in many, many markets as well as the Hengrui assets starting to commercialize in some of the markets by F '28. So I think the real uplift in the margin profile of the company will happen from the current 23-odd levels, right, will happen from F '28 onwards."

Europe: Normalizing After a Super-Cycle

• Growth trajectory reset: After a 25% CAGR over the last 3–4 years, Europe faced growth challenges in the first half; going forward, management expects single-digit to low-double-digit growth given the high base.
• Growth drivers intact: At least a couple of respiratory product launches expected in FY27, incremental RYALTRIS growth, WINLEVI launch in UK and Europe, and increasing branded market contribution.
• Q3 recovery: Onset of winter season aided the respiratory portfolio, driving the quarterly rebound.

Glenn Saldanha: "Given that we've grown our 25% CAGR over the last 3, 4 years... you should expect like a single-digit to low-double-digit growth from here."

Guidance & Commitments

Key Metrics